Anavex Life Sciences (AVXL) saw its stock price plummet 5.15% in intraday trading, despite reporting better-than-expected earnings for the quarter ended March 31, 2025. The biotech company posted a quarterly loss of 13 cents per share, outperforming analyst expectations of a 15 cents per share loss.

Despite the earnings beat, investors appear to be concerned about Anavex's ongoing financial challenges. The company reported a quarterly loss of $11.2 million and zero revenue, highlighting the continued cash burn typical of early-stage biotech firms. This performance comes against a backdrop of a 20.4% year-to-date decline in Anavex's stock price, suggesting persistent investor skepticism about the company's near-term prospects.

While Wall Street maintains a "buy" rating on Anavex shares with a median 12-month price target of $42.00, today's stock movement indicates that investors may be growing impatient with the company's path to profitability. As Anavex continues to invest in its pipeline of potential treatments for central nervous system disorders, the market will be closely watching for signs of revenue generation and reduced losses in future quarters.